Terminated PHASE2 INTERVENTIONAL 1-arm NCT00895648

Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma

Phase II Study of Neo-adjuvant Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Malignant Pleural Mesothelioma

Sponsor: Eli Lilly and Company

Conditions Mesothelioma Pleural Mesothelioma

Interventions Cisplatin Pemetrexed

Updated 5 times since 2017 Last updated: May 3, 2017 Started: Jan 31, 2009 Primary completion: Oct 31, 2012 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

low accrual due to competing study for same group of patients

Other terminated trials from Eli Lilly and Company

See all terminations from Eli Lilly and Company

Other Mesothelioma trials with similar outcome

Browse all Mesothelioma trials

A PHASE2 clinical study on Mesothelioma and Pleural Mesothelioma, this trial is terminated or withdrawn. The trial is conducted by Eli Lilly and Company and has accumulated 5 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada